Donna F Vine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1348885/publications.pdf Version: 2024-02-01



DONNA E VINE

#	Article	IF	CITATIONS
1	Human health benefits of vaccenic acid. Applied Physiology, Nutrition and Metabolism, 2009, 34, 979-991.	0.9	211
2	Arterial retention of apolipoprotein B48- and B100-containing lipoproteins in atherogenesis. Current Opinion in Lipidology, 2002, 13, 461-470.	1.2	173
3	Trans-11 Vaccenic Acid Dietary Supplementation Induces Hypolipidemic Effects in JCR:LA-cp Rats. Journal of Nutrition, 2008, 138, 2117-2122.	1.3	143
4	Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertility and Sterility, 2012, 98, 185-193.e2.	0.5	103
5	Trans-11 Vaccenic Acid Reduces Hepatic Lipogenesis and Chylomicron Secretion in JCR:LA-cp Rats. Journal of Nutrition, 2009, 139, 2049-2054.	1.3	59
6	Chronic dietary <i>n</i> -3 PUFA intervention improves dyslipidaemia and subsequent cardiovascular complications in the JCR:LA- <i>cp</i> rat model of the metabolic syndrome. British Journal of Nutrition, 2011, 105, 1572-1582.	1.2	54
7	A Unique Rodent Model of Cardiometabolic Risk Associated with the Metabolic Syndrome and Polycystic Ovary Syndrome. Endocrinology, 2009, 150, 4425-4436.	1.4	46
8	Increased hypolipidemic benefits of cis-9, trans-11 conjugated linoleic acid in combination with trans-11 vaccenic acid in a rodent model of the metabolic syndrome, the JCR:LA-cp rat. Nutrition and Metabolism, 2010, 7, 60.	1.3	39
9	The intestinal bioavailability of vaccenic acid and activation of peroxisome proliferatorâ€activated receptorâ€Î± and â€Î³ in a rodent model of dyslipidemia and the metabolic syndrome. Molecular Nutrition and Food Research, 2012, 56, 1234-1246.	1.5	37
10	Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors. Journal of Nutrition, 2017, 147, 473-481.	1.3	32
11	The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3452-3460.	1.8	32
12	Intestinal lipid transport and chylomicron production: Possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atherosclerosis Supplements, 2008, 9, 69-76.	1.2	30
13	Vaccenic acid suppresses intestinal inflammation by increasing anandamide and related N-acylethanolamines in the JCR:LA-cp rat. Journal of Lipid Research, 2016, 57, 638-649.	2.0	30
14	Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E16-E33.	1.8	27
15	Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents with Polycystic Ovary Syndrome Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-2854.	1.8	25
16	Simvastatin treatment upregulates intestinal lipid secretion pathways in a rodent model of the metabolic syndrome. Atherosclerosis, 2014, 232, 141-148.	0.4	24
17	Vaccenic and Elaidic Acid Modify Plasma and Splenocyte Membrane Phospholipids and Mitogen-Stimulated Cytokine Production in Obese Insulin Resistant JCR: LA-cp Rats. Nutrients, 2010, 2, 181-197.	1.7	18
18	Beneficial effects of vaccenic acid on postprandial lipid metabolism and dyslipidemia: Impact of natural <i>trans</i> â€fats to improve CVD risk. Lipid Technology, 2010, 22, 103-106.	0.3	17

Donna F Vine

#	Article	IF	CITATIONS
19	Angiotensin II Type 2 Receptor Stimulation Improves Fatty Acid Ovarian Uptake and Hyperandrogenemia in an Obese Rat Model of Polycystic Ovary Syndrome. Endocrinology, 2014, 155, 3684-3693.	1.4	17
20	Mechanisms of Comorbidities Associated With the Metabolic Syndrome: Insights from the JCR:LA-cp Corpulent Rat Strain. Frontiers in Nutrition, 2016, 3, 44.	1.6	12
21	ApoB48-remnant lipoproteins are associated with increased cardiometabolic risk in adolescents. Atherosclerosis, 2020, 302, 20-26.	0.4	12
22	Cardiometabolic and reproductive benefits of early dietary energy restriction and voluntary exercise in an obese PCOS-prone rodent model. Journal of Endocrinology, 2015, 226, 193-206.	1.2	10
23	Beef Fat Enriched with Polyunsaturated Fatty Acid Biohydrogenation Products Improves Insulin Sensitivity Without Altering Dyslipidemia in Insulin Resistant JCR:LAâ€∢i>cp Rats. Lipids, 2016, 51, 821-831.	0.7	10
24	Sex Differences Distinctly Impact High-Fat Diet-Induced Immune Dysfunction in Wistar Rats. Journal of Nutrition, 2022, 152, 1347-1357.	1.3	10
25	ApoB48-Lipoproteins Are Associated with Cardiometabolic Risk in Adolescents with and without Polycystic Ovary Syndrome. Journal of the Endocrine Society, 2020, 4, bvaa061.	0.1	9
26	Down-regulation of hypothalamic pro-opiomelanocortin (POMC) expression after weaning is associated with hyperphagia-induced obesity in JCR rats overexpressing neuropeptide Y. British Journal of Nutrition, 2014, 111, 924-932.	1.2	7
27	Prior caloric restriction increases survival of prepubertal obese- and PCOS-prone rats exposed to a challenge of time-limited feeding and physical activity. Journal of Applied Physiology, 2013, 114, 1158-1164.	1.2	6
28	Intestinal lymphatic HDL miRâ€223 and ApoAâ€I are reduced during insulin resistance and restored with niacin. FASEB Journal, 2018, 32, 1602-1612.	0.2	6
29	<scp>ApoBâ€lipoprotein</scp> remnant dyslipidemia and <scp>highâ€fat</scp> meal intolerance is associated with markers of cardiometabolic risk in youth with obesity. Pediatric Obesity, 2021, 16, e12745.	1.4	6
30	Interrelationship of CB1R and OBR pathways in regulation of metabolic, neuroendocrine, and behavioral responses to food restriction and voluntary wheel running. Journal of Applied Physiology, 2014, 117, 97-104.	1.2	4
31	A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome. Journal of the Endocrine Society, 2021, 5, bvab114.	0.1	4
32	Does changing the PUFA content of a high saturated fat meal influence postprandial lipid and lipoprotein expression in children with nonalcoholic fatty liver disease?. FASEB Journal, 2012, 26, 252.3.	0.2	0